Ironwood Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133 million, GAAP net income of $60 million, and record adjusted EBITDA of $98 million.
- LINZESS Q3 net sales were $325 million and year-to-date net sales were $880 million, driven primarily by improved net price; EU TRX demand volume grew 5% year over year.
- Ironwood paid down $60 million of its revolving credit facility during the quarter, ending Q3 with an outstanding principal balance of $325 million, $86 million in cash and cash equivalents, and $133 million in collaboration receivables.
- STARS-2 is a randomized, double-blind, placebo-controlled, 24-week confirmatory Phase 3 trial of apreglutide in adults with short bowel syndrome with intestinal failure.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q3 2026 Investor Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. Thank you. I would now like to turn the call over to Chris Stamm, VP of Investor Relations and Communications.
Please go ahead. Good morning, and thanks for joining our third quarter 2026 investor update call.
A press release issued this morning highlighting third quarter results can be found on our website. Today's call and accompanying slides include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current safe harbor statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2025, and in our subsequent SEC filings. All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements.
Also included are non-GAAP financial measures, which should be considered only as a supplement to and not a substitute for or superior to GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Chief Executive Officer Tom McCourt will review third quarter business highlights and our progress advancing our 2026 strategic priorities. Following Tom, Chief Commercial Officer and CEO Elect Tammi Gaskins will provide an overview of third quarter LINZESS performance. Next, Jeff Silber, our Chief Medical Officer and Head of Research and Drug Development, will provide an update on apraglutide and the STARS-2 trial.
Ron Silver, our Interim Chief Financial Officer, will provide a financial update before turning the call back to Tom and Tammy for some closing remarks prior to opening the call for questions. Jeff Ruberti, Ironwood's Chief Strategy Officer, will also be available during the Q&A portion of the call. Today's webcast includes accompanying slides. For those joining by phone, please visit the Events section of our website to access the presentation. With that, I'll turn the call over to Tom.
Thanks, Chris, and thank you all for joining us this morning to review Ironwood's third quarter 2026 financial results and business updates. Ironwood's momentum carried into the third quarter as we continued our focused execution across three strategic priorities: maximizing the value of LINZESS, advancing the development of apraglutide, and delivering sustained profits and cash flow. 2026 continues to be a turnaround year for the company as we make meaningful progress across each of these priorities. We believe LINZESS is on its way to returning to blockbuster status this year, demonstrating exceptional durability and growth in its 14th year on the market and remaining the U.S. branded leading prescription therapy for both IBS-C and chronic constipation.
We delivered a strong third quarter, and based on this momentum, are once again raising our full year 2026 LINZESS guidance, now to the range of $1.2 billion-$1.25 billion, representing growth of more than 35% year-over-year. Turning to apraglutide, we continue to advance the global rollout of the STARS-2, our confirmatory phase III trial evaluating apraglutide in patients with short bowel syndrome with intestinal failure, with our plans for clinical trial site activation progressing across the U.S. and internationally. Building on the positive results from the phase III STARS trial, STARS-2 is designed to confirm apraglutide's efficacy in reducing parenteral support requirements. We believe the strength of the STARS data and apraglutide's once-weekly administration has potential to deliver a meaningful benefit to patients with short bowel syndrome who are dependent on parenteral support.
Finally, we delivered strong financial results during the quarter, generating $60 million in GAAP net income and a record $98 million in adjusted EBITDA. Looking ahead, we expect to utilize LINZESS-generated cash flow to further reduce our debt and are well-positioned to end 2026 with a gross leverage below 1X, while maintaining resources necessary to advance and prepare for the potential commercialization of apraglutide. With that, I'll ask Tammy to provide some additional context on LINZESS.
Thanks, Tom, and good morning, everyone. As Tom noted, this quarter continues a remarkable turnaround for LINZESS, highlighting the strength of the brand's prescription market leadership. In summary, Q3 net sales for LINZESS came in at $325 million, with year-to-date net sales of $880 million through Q3, driven primarily by improved net price. In addition to price, EU TRX demand volume growth of 5% year-over-year has also supported year-to-date net sales, with mid-single-digit demand growth still expected for the full year. This slide, as you see, also reflects the steadiness in consecutive quarterly net sales because of greater price consistency across channels versus prior year. LINZESS year-to-date net sales of $880 million has already exceeded full-year 2025 net sales, and we expect Q4 to be our strongest quarter of the year.
The strong finish to the year is expected to be driven by continued demand and improved net price relating to the elimination of inflationary rebates across channels and fewer Medicare Part D patients reaching the catastrophic phase resulting from the lower list price. These factors support the raise of our full-year LINZESS net sales guidance by $50 million-$1.20 billion-$1.25 billion, representing growth of more than 35% year over year. Most importantly, LINZESS continues to be prescribed to help address the unmet needs of millions of patients with IBS-C and CIC. Now I'd like to pass the presentation over to my colleague, Jeff Silber, to highlight the latest updates regarding the apraglutide program.
Jeff? Thanks, Tammy, and good morning, everyone.
This quarter, we continue to advance STARS-2, our randomized, double-blind, placebo-controlled 24-week confirmatory phase III trial evaluating apraglutide in adults with short bowel syndrome with intestinal failure, or SBS-IF. As with any clinical trial, the pathway to ramping up patient enrollment runs through broad site activation. To this end, I'm happy to share that as we continue to add sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities, and these are now either under review or already approved. We remain on track with our plans to activate more than 100 clinical trial sites across 22 countries, spanning the Americas, Europe, and Asia Pacific, establishing a broad global network to support patient recruitment. At this stage, the activated sites have begun recruiting patients.
STARS-2 is designed with a substantially expanded global clinical trial network compared with the original STARS study, which involved 68 sites. STARS-2 includes approximately twice as many planned U.S. sites, representing a thoughtful effort to accelerate patient recruitment and study execution. As a reminder, apraglutide is the only once-weekly GLP-2 analog to demonstrate positive phase III efficacy data and a favorable safety profile in adults with SBS-IF based on the results of the STARS study. As you can see on the left, in the STARS trial, the group receiving apraglutide once weekly achieved a statistically significant reduction in weekly parenteral support volume compared with the placebo recipients at week 24. In fact, patients receiving apraglutide experienced approximately twice the percentage reduction observed with placebo.
Importantly, more than 90% of the STARS patients opted to enroll in the STARS Extend long-term extension study, and of these, about three-quarters remain on treatment, with some having received apraglutide for up to five years. As shown on the right, patients in STARS Extend continued to decrease their parenteral support requirements over time, with some gaining incremental days off, including achievement of enteral autonomy, highlighting the potential for continued reductions in parenteral support requirements with longer-term apraglutide treatment. We believe that patients will be motivated to stay on apraglutide long-term because of the potential for ongoing clinical benefit, the convenience of once-weekly administration, and an observed safety and tolerability profile to date that would enable sustained use. We remain encouraged by the evolving long-term findings from STARS Extend, and we look forward to presenting updated clinical results from the study at medical congresses in the first half of 2027.
Our overall goal remains to get apraglutide to patients as quickly as possible, and if approved, to be the first long-acting GLP-2 analog for patients with SBS-IF in the U.S. I look forward to providing additional details on the progress of STARS-2 during our 4Q update. With that, I will turn the call over to Ron.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
